Liquid-Filled Hard Gel Capsule Formulation for Dutasteride
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The manufacturing of soft gel capsule formulations for dutasteride is cost-intensive and inefficient due to a slow and burdensome process, necessitating the development of improved hard gel capsule formulations that maintain bioavailability and stability while reducing manufacturing costs.
Innovation Solution
A liquid-filled hard gel capsule formulation comprising a non-emulsified mixture of 0.1 to 5% active pharmaceutical ingredient, 50 to 95% medium or long chain triglycerides, and 5 to 25% medium chain mono/diglycerides, with a specific ratio of triglycerides to mono/diglycerides, which does not require drying and uses a hard gelatin capsule shell to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If soft gel capsule formulations are used for dutasteride, then bioavailability and stability are maintained, but manufacturing costs increase and production efficiency decreases
Solution Approach 1:
The patent changes the capsule shell type from soft gelatin to hard gelatin, and modifies the internal formulation from an emulsified system to a non-emulsified system with specific triglyceride/mono-glyceride ratios. These parameter changes enable the formulation to achieve comparable bioavailability and stability while allowing for faster, more cost-effective manufacturing processes that do not require drying steps.
2Reliability
If soft gel capsule formulations are used for dutasteride, then bioavailability and stability are maintained, but manufacturing costs increase
Solution Approach 1:
The patent changes the capsule shell type from soft gelatin to hard gelatin, and modifies the internal formulation from an emulsified system to a non-emulsified system with specific triglyceride/mono-glyceride ratios. These parameter changes enable the formulation to achieve comparable bioavailability and stability while allowing for faster, more cost-effective manufacturing processes that do not require drying steps.
3Productivity
If hard gel capsule formulations are used to reduce manufacturing costs, then production efficiency improves, but bioavailability and stability may be compromised
Solution Approach 1:
The patent uses a composite lipid system comprising medium chain triglycerides and medium chain mono/diglycerides in a specific weight ratio (2:1 to 4:1). This composite material system provides the necessary solubility and stability for dutasteride while enabling hard capsule formulation, thus achieving both manufacturing efficiency and drug performance requirements.
Solution Approach 2:
The patent changes the capsule shell type from soft gelatin to hard gelatin, and modifies the internal formulation from an emulsified system to a non-emulsified system with specific triglyceride/mono-glyceride ratios. These parameter changes enable the formulation to achieve comparable bioavailability and stability while allowing for faster, more cost-effective manufacturing processes that do not require drying steps.
4Quantity of substance
If emulsified mixtures are used in hard gel capsules, then drug solubility improves, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts and eliminates the emulsification step and emulsifying agents from the formulation process. Instead of using complex emulsified systems, the invention employs a non-emulsified mixture of triglycerides and mono/diglycerides that naturally solubilizes dutasteride, thereby reducing formulation complexity while maintaining drug solubility.
Solution Approach 2:
The patent uses a composite lipid system comprising medium chain triglycerides and medium chain mono/diglycerides in a specific weight ratio (2:1 to 4:1). This composite material system provides the necessary solubility for dutasteride without requiring emulsification, thus simplifying the formulation while maintaining drug solubility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation reduces manufacturing costs and maintains bioavailability and stability of dutasteride, offering thermal stability and avoiding issues of moisture sensitivity and plasticizer migration, with a faster production process compared to soft gel capsules.
Implementation Method 1
a non-emulsified mixture disposed in a hard capsule shell, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight medium chain triglycerides, and about 5 to about 25% by weight medium chain mono/diglycerides
Implementation Method 2
a hard gelatin capsule shell to enhance stability and bioavailability
Implementation Method 3
offering thermal stability and avoiding issues of moisture sensitivity and plasticizer migration
Data Source
AI summary
Embodiments of liquid-filled hard gel capsule pharmaceutical formulations comprise a non-emulsified mixture, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight medium chain triglycerides, and about 5 to about 25% by weight medium chain mono/diglycerides, wherein the medium chain triglycerides and medium chain mono/diglycerides are present at a ratio by weight of from about 10:1 to about 5:1.